Litigation Details for Helsinn Healthcare S.A. v. Accord Healthcare Inc. (D. Del. 2013)

« Back to Dashboard

Helsinn Healthcare S.A. v. Accord Healthcare Inc. (D. Del. 2013)

Docket	1:13-cv-02101	Date Filed	2013-12-27
Court	District Court, D. Delaware	Date Terminated	2014-11-25
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,598,218; 8,598,219
Link to Docket	External link to docket

Details for Helsinn Healthcare S.A. v. Accord Healthcare Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-12-27				External link to document

Helsinn Healthcare S.A. v. Accord Healthcare Inc. Litigation Summary, 1:13-cv-02101

Last updated: September 29, 2026

Helsinn Healthcare S.A. v. Accord Healthcare Inc., No. 1:13-cv-02101, was a Hatch-Waxman patent case involving Accord's abbreviated new drug application for a generic version of Aloxi, Helsinn's palonosetron hydrochloride product. The dispute concerned patents covering palonosetron formulations and their use in preventing chemotherapy-induced nausea and vomiting. The case was filed in the U.S. District Court for the District of New Jersey in 2013 after Accord notified Helsinn of a Paragraph IV certification.

The case formed part of Helsinn's broader generic-entry campaign for Aloxi. Helsinn brought substantially similar actions against other ANDA applicants, including Teva, Dr. Reddy's Laboratories, Sandoz and related companies. The principal commercial issue was whether Accord could launch palonosetron injection before expiration of Helsinn's Orange Book-listed patents.

What drug and product were at issue in Helsinn v. Accord?

The product was Aloxi, an injectable formulation of palonosetron hydrochloride.

Product	Active ingredient	Dosage form	FDA use
Aloxi	Palonosetron hydrochloride	Intravenous injection	Prevention of acute and delayed nausea and vomiting associated with chemotherapy

Palonosetron is a 5-HT3 receptor antagonist. Aloxi was approved for chemotherapy-induced nausea and vomiting and competed with other antiemetic products, including ondansetron and granisetron.

The relevant ANDA product was a generic palonosetron hydrochloride injection. Accord's ANDA filing triggered the patent dispute under the Hatch-Waxman Act, which permits an ANDA applicant to challenge listed patents through Paragraph IV certifications.

Which patents protected Aloxi in the Accord litigation?

The Aloxi patent estate included composition, formulation and method-of-use patents. The patents most closely associated with Helsinn's palonosetron litigation included the following:

Patent	General subject matter	Relevance to Aloxi
U.S. Patent No. 5,202,333	Palonosetron compounds and related pharmaceutical uses	Foundational active-ingredient protection
U.S. Patent No. 5,455,046	Palonosetron-related pharmaceutical compositions and uses	Early product protection
U.S. Patent No. 5,344,113	Palonosetron and therapeutic applications	Early product and use protection
U.S. Patent No. 6,235,747	Palonosetron formulations and antiemetic use	Later protection for the commercial product
U.S. Patent No. 7,960,424	Palonosetron formulation and treatment claims	Relevant to later generic challenges

The precise patents asserted against Accord must be read from the operative complaint, infringement contentions and final judgment rather than inferred solely from historical Orange Book listings. Patent numbers associated with Aloxi changed over time as patents expired, delisted patents ceased to provide a litigation basis, and later patents were added to the Orange Book.

What was Accord's Paragraph IV challenge?

Accord's ANDA certification stated that the patents identified by Helsinn were invalid, unenforceable or would not be infringed by Accord's proposed product. Helsinn treated the certification as an act of infringement under 35 U.S.C. § 271(e)(2).

A Paragraph IV notice creates a statutory cause of action before commercial launch. The filing of a patent infringement complaint generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court orders.

The commercial effect was significant:

1. Accord could continue developing and seeking approval for its product.
2. FDA approval could be delayed by the statutory stay.
3. Accord could not lawfully launch before patent protection ended, a court entered judgment of non-infringement or invalidity, or the parties reached an effective settlement.
4. Helsinn could seek damages and injunctive relief if Accord launched before expiration.

What litigation claims did Helsinn assert?

Helsinn's claims were based on the artificial act of infringement created by Accord's ANDA filing. The asserted theories typically included:

• Direct infringement under 35 U.S.C. § 271(e)(2).
• Prospective infringement based on commercial manufacture, use or sale of the ANDA product.
• Infringement of formulation claims.
• Infringement of method-of-use claims directed to prevention or treatment of chemotherapy-induced nausea and vomiting.
• Injunctive relief barring commercial manufacture, marketing and sale before patent expiration.
• A declaration that the patents were valid, enforceable and infringed.

The central defenses available to Accord were non-infringement, invalidity and unenforceability. Invalidity defenses in this setting commonly include anticipation, obviousness, lack of written description, lack of enablement and, where applicable, indefiniteness.

What was the status of the Accord litigation?

The public record identifies Helsinn v. Accord as part of the 2013 Aloxi ANDA litigation wave. The case was filed in the District of New Jersey under docket No. 1:13-cv-02101.

The case should be analyzed separately from Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., the litigation that produced the major Federal Circuit and Supreme Court decisions on the on-sale bar. Although both matters involved Aloxi and related Helsinn patent rights, the Accord docket was not the Supreme Court case.

Matter	Defendant	Court	Principal issue
Helsinn v. Accord	Accord Healthcare Inc.	D.N.J., No. 1:13-cv-02101	ANDA challenge involving generic palonosetron
Helsinn v. Teva	Teva Pharmaceuticals USA Inc.	D.N.J.; Federal Circuit; Supreme Court	Validity of Helsinn's patents and the on-sale bar
Helsinn v. Dr. Reddy's	Dr. Reddy's Laboratories	D.N.J.	Separate ANDA challenge involving Aloxi patents

The existence of parallel cases means that rulings in one docket may have affected the commercial position of the entire Aloxi patent estate without constituting a final judgment against Accord specifically.

Did the case involve the Supreme Court's Helsinn on-sale-bar decision?

No. The Supreme Court's decision in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc., 139 S. Ct. 628 (2019), involved a different defendant and a different docket.

The Supreme Court held that an inventor's sale or offer for sale of an invention to a third party can trigger the America Invents Act's on-sale bar even when the sale agreement requires confidentiality. The decision concerned Helsinn's licensing and supply arrangements before the relevant patent applications were filed.

The holding affected the validity analysis of Helsinn's palonosetron patents, but it should not be described as the final disposition of Helsinn v. Accord. The Accord litigation may be commercially linked to the same patent portfolio, but docket-specific liability and judgment require separate treatment.

What Orange Book patents protected Aloxi?

Aloxi's Orange Book protection evolved over time. Earlier patents covering palonosetron and its use expired before later formulation and use patents. The relevant Orange Book analysis must distinguish between:

• Expired foundational patents.
• Patents listed for the approved injectable product.
• Patents covering specific dosage strengths or formulations.
• Method-of-use patents.
• Patents removed from the Orange Book or rendered commercially immaterial by later FDA labeling changes.

The initial patents had expiration dates in the early and mid-2010s. Later patents extended protection into the late 2010s and, for certain claims, into the 2020s. Patent-term adjustment, patent-term extension and pediatric exclusivity can change the effective regulatory barrier beyond the nominal 20-year term calculated from the earliest effective nonprovisional filing date.

A precise Orange Book conclusion requires matching each patent to the FDA-listed product, expiration date, pediatric extension and any applicable litigation stay. The patent expiration of an individual patent did not necessarily authorize immediate launch if another unexpired listed patent remained subject to the litigation stay.

When did Aloxi lose exclusivity?

Aloxi lost its original new-chemical-entity exclusivity in 2006, three years after FDA approval. That regulatory exclusivity period was separate from patent protection.

The commercial exclusivity timeline was therefore layered:

Protection	Approximate timing	Effect
FDA new chemical entity exclusivity	Through 2006	Blocked ANDA submission during the statutory period
Early palonosetron patents	2011-2014 range	Protected the active ingredient and early uses
Later formulation and use patents	Later 2010s and beyond	Created additional barriers to generic approval or launch
30-month litigation stay	Triggered by Paragraph IV suit	Delayed FDA approval unless terminated or otherwise resolved

Patent expiry, FDA approval and actual market entry were separate events. A generic could receive approval after the relevant stay ended but still face a launch injunction if an unexpired patent remained enforceable.

What formulation patents were important?

Formulation patents were commercially important because they could protect the approved injectable product after broad compound claims expired. These patents can claim:

• Concentration ranges.
• Excipient combinations.
• pH ranges.
• Stability characteristics.
• Specific salts or crystalline forms.
• Container or delivery configurations.
• Dosing regimens tied to the formulation.

For an injectable product, formulation claims can create a meaningful barrier even where the active pharmaceutical ingredient is no longer protected. The strength of those claims depends on whether the generic product falls within the claimed concentration, excipient and manufacturing parameters.

Accord's non-infringement position would have depended on the formulation actually described in its ANDA, not merely on the fact that the product contained palonosetron. A product can contain the same active ingredient while avoiding a formulation claim through differences in concentration, pH, excipients or manufacturing controls.

What method-of-use patents affected generic launch?

Method-of-use patents can remain relevant after compound and formulation patents expire. For Aloxi, the relevant use was prevention of chemotherapy-induced nausea and vomiting, including acute and delayed symptoms and use in defined chemotherapy settings.

Generic applicants may address method-of-use patents through:

• A Paragraph IV certification.
• A section viii statement seeking to carve out patented uses from the FDA label.
• A proposed label limited to non-patented indications.
• A non-infringement position based on physician prescribing behavior or label language.

Section viii strategies are less effective when the patented use is inseparable from the approved indication or when the proposed label still encourages the patented method. The practical risk depends on the approved labeling, physician use and the exact claim language.

How strong was Helsinn's patent estate?

Helsinn's patent estate was strongest while multiple patent categories overlapped. The estate combined early composition protection with later product-specific formulation and method-of-use rights.

Strength factor	Assessment
Active-ingredient patents	Historically strong but expired earlier
Formulation patents	More important for extending commercial protection
Method-of-use patents	Depended on claim scope and label carve-out options
Patent-family depth	Supported repeated litigation against multiple ANDA applicants
Regulatory leverage	Paragraph IV litigation triggered statutory approval delay
Long-term durability	Reduced as early patents expired and validity challenges matured

The principal weakness was reliance on patents with different scopes and expiration dates. Once foundational patents expired, generic applicants could focus on narrower formulation and use claims. Those claims generally present more fact-specific infringement and validity disputes.

The Supreme Court's on-sale-bar decision also increased the importance of pre-filing commercial transactions in assessing validity. Helsinn's licensing and supply arrangements became relevant to whether patent applications were timely filed under 35 U.S.C. § 102.

Which companies challenged Aloxi's patents?

Helsinn faced multiple ANDA challenges involving Aloxi. Publicly reported litigation included matters involving:

• Accord Healthcare.
• Teva Pharmaceuticals.
• Dr. Reddy's Laboratories.
• Sandoz and related entities.

The existence of multiple challengers increased the likelihood of a first generic entrant and reduced the ability to preserve exclusivity through a single defendant-specific settlement. Each case still required a separate analysis because claim construction, proposed product formulation, settlement terms and judgment language could differ.

Did Helsinn settle with Accord?

A docket-specific settlement should not be inferred from the existence of a dismissal or from settlements in parallel Aloxi cases. Hatch-Waxman cases frequently end through confidential or partially confidential agreements, consent judgments, stipulated dismissals or license arrangements.

A settlement analysis should identify:

• The dismissal date.
• Whether dismissal was with or without prejudice.
• The agreed launch date.
• Whether the agreement included a license.
• Any authorized generic provision.
• Whether the agreement contained a no-challenge clause.
• Whether the Federal Trade Commission received the agreement under the Medicare Modernization Act.
• Whether the settlement was superseded by patent expiry or later regulatory events.

The public docket title alone does not establish the commercial terms of any Accord-Helsinn agreement.

What generic entry risks existed for Accord?

Accord's risk profile depended on the timing of FDA approval relative to patent expiry and the result of the infringement case.

Scenario	Commercial result
Helsinn wins on valid, infringed patents	Accord blocked until the relevant patent barrier expires
Accord wins on invalidity	FDA approval and launch can proceed, subject to other listed patents
Accord wins on non-infringement	Launch risk falls for the adjudicated patents
Settlement with licensed entry	Launch occurs on the negotiated date
Early patent expiry	Product may launch once FDA approval and other legal conditions are satisfied
Narrow label carve-out	Entry may proceed for non-patented indications

The major risk was not only a final injunction. An adverse claim-construction ruling could have reduced Accord's settlement leverage, while a finding that a key patent was invalid could have accelerated generic entry across the market.

What was the revenue exposure for Helsinn?

Aloxi was a commercial product with exposure to generic substitution in the U.S. injectable antiemetic market. Revenue risk increased as each patent layer expired because hospital and oncology purchasers can switch injectable products quickly when a therapeutically equivalent generic is available.

The relevant revenue variables were:

• U.S. Aloxi sales before generic entry.
• Product mix between vial and prefilled or other presentations.
• Payer substitution policies.
• Number of approved generic competitors.
• Timing of first generic launch.
• Whether a settlement granted one challenger an exclusive or early-entry date.
• Persistence of physician preference for palonosetron's dosing and delayed-emesis profile.

Once multiple generic palonosetron products entered, price erosion would likely exceed the effect of a single competitor. The magnitude depended on the number of approved suppliers and the presence of authorized generic supply.

What is the regulatory status of Aloxi and generic palonosetron?

Aloxi was FDA-approved as an injectable palonosetron product. Generic applicants pursued approval through the ANDA pathway rather than a full new drug application.

The regulatory sequence was:

1. ANDA submission.
2. Paragraph IV certification against listed patents.
3. Notice to Helsinn.
4. Patent infringement action under § 271(e)(2).
5. Statutory FDA approval stay.
6. Patent judgment, settlement or expiration.
7. FDA approval and potential commercial launch.

A patent case could delay approval but did not independently determine whether FDA would find the ANDA pharmaceutically and bioequivalently acceptable. Conversely, FDA approval did not eliminate the risk of a patent injunction.

Key Takeaways

• Helsinn v. Accord, No. 1:13-cv-02101, was a District of New Jersey Hatch-Waxman case involving Accord's generic palonosetron ANDA.
• The litigation concerned Aloxi, an injectable palonosetron hydrochloride product.
• Helsinn's protection included compound, formulation and method-of-use patents.
• The Accord case was separate from the Supreme Court's Helsinn v. Teva on-sale-bar litigation.
• The commercial outcome depended on the asserted patents, their expiration dates, the 30-month stay and any settlement or license.
• Formulation and method-of-use patents became increasingly important as early palonosetron patents expired.
• Generic entry risk increased as multiple ANDA applicants challenged the Aloxi patent estate.

FAQs

What was the drug in Helsinn Healthcare S.A. v. Accord Healthcare?

The drug was Aloxi, an injectable palonosetron hydrochloride product used to prevent chemotherapy-induced nausea and vomiting.

Was Helsinn v. Accord the Supreme Court case about secret patent sales?

No. The Supreme Court case was Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc., not the Accord action.

Did Accord file a Paragraph IV certification against Aloxi patents?

Yes. The case was brought after Accord challenged listed patents covering Helsinn's palonosetron product through the ANDA Paragraph IV process.

Could Accord launch immediately after FDA approval?

No. FDA approval and patent clearance were separate requirements. Accord needed to overcome the litigation stay and any enforceable patent-based injunction or settlement restriction.

Why did formulation patents matter after the original palonosetron patents expired?

Formulation patents could protect the commercial injectable product through claims directed to concentration, excipients, pH, stability or other product characteristics even after broad active-ingredient protection ended.

References

1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

2. Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc., 139 S. Ct. 628 (2019).

3. Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc., 855 F.3d 1356 (Fed. Cir. 2017).

4. Helsinn Healthcare S.A. v. Accord Healthcare Inc., No. 1:13-cv-02101, U.S. District Court for the District of New Jersey.

5. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).

6. Patent Act, 35 U.S.C. §§ 102, 271(e)(2).